CV Sciences, Inc. (CVSI)
OTCMKTS · Delayed Price · Currency is USD
0.0327
-0.0073 (-18.25%)
Mar 25, 2026, 1:08 PM EST
CV Sciences Revenue
CV Sciences had revenue of $3.26M in the quarter ending September 30, 2025, a decrease of -15.76%. This brings the company's revenue in the last twelve months to $14.37M, down -8.04% year-over-year. In the year 2024, CV Sciences had annual revenue of $15.71M, down -1.87%.
Revenue (ttm)
14.37M
Revenue Growth
-8.04%
P/S Ratio
0.47
Revenue / Employee
299.29K
Employees
49
Market Cap
6.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.71M | -299.00K | -1.87% |
| Dec 31, 2023 | 16.00M | -201.00K | -1.24% |
| Dec 31, 2022 | 16.21M | -3.84M | -19.17% |
| Dec 31, 2021 | 20.05M | -4.38M | -17.93% |
| Dec 31, 2020 | 24.43M | -29.27M | -54.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trees | 14.50M |
| CordovaCann | 10.25M |
| Tristar Wellness Solutions | 4.00M |
| Bio Essence | 565.67K |
| Rafarma Pharmaceuticals | 133.33K |
| Cannabis Bioscience International Holdings | 127.35K |
| Indo Global Exchange(s) PTE | 3.49K |
CV Sciences News
- 22 hours ago - CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 - Accesswire
- 14 days ago - CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth - Accesswire
- 27 days ago - CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness - Accesswire
- 3 months ago - CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD - Accesswire
- 4 months ago - CV Sciences, Inc. (CVSI) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 4 months ago - CV Sciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 4 months ago - CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 - Accesswire
- 7 months ago - CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & Focus - Accesswire